Illumina CEO Says Next Round of GWAS Will Be Done on Arrays, Not Sequencers | GenomeWeb

This story was originally posted on Jan. 15.

By Justin Petrone

Though Illumina was "handed a number of challenges in 2009," including slowing demand for its whole-genome genotyping arrays from researchers conducting genome-wide association studies, the company's CEO last week said that he is confident the market's appetite for arrays will revive this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.